Sign up USA
Proactive Investors - Run By Investors For Investors
EPIC: AKR
Market: AIM
Sector: Health Care, Equipment & Services
Phone: +1 856 848 8698
Address: 201 Grove Road, Thorofare, West Deptford, NJ 08086.
Website: www.akersbio.com
Akers Biosciences, Inc.

Akers Biosciences, Inc.

Akers Biosciences develops, manufactures, and supplies rapid diagnostic tests for hospital laboratories, government, military, law enforcement, on-the-job safety, doctors’ offices and home use. The company aims to bring healthcare information both rapidly and directly to the consumer or healthcare provider. Akers’ state-of-the-art rapid diagnostic tests can be performed virtually anywhere, in minutes and when time is of the essence. Akers already has sales from commercialised products targeting large testing markets, with other tests in development including the first to identify the presence of lung cancer through the breath. Akers is underpinned by a valuable proprietary platform technology base. 

Akers Biosciences, Inc.

www.akersbio.com

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in Akers Biosciences, Inc.


Akers Biosciences, Inc. Snapshot

Our Founding

ABI was founded in 1989, with the objective of developing proprietary, in vitro diagnostic technologies that accelerate the rate at which clinicians can obtain single-patient results.  The tests and sample preparation devices that emerge from our rapid technology platforms are designed to provide the same level of accuracy as traditional laboratory testing methods, but at a fraction of the cost and turn-around time.

 

Our Inspiration

We our dedicated to the development of time- and cost-efficient, single-use devices that can be utilized almost anytime, anywhere.  We believe that our products facilitate more convenient and frequent point-of-care testing which may ultimately save or improve the overall quality of individuals’ lives.

 

Our Products

Our rapid diagnostic tests, specifically designed for healthcare applications:

 

  • help facilitate or rule-out diagnoses and provide a targeted pathway for real-time treatment decisions
  • provide affordable testing solutions for mass screenings for key infectious diseases, cardiac conditions and metabolic markers, without the use of expensive equipment or lengthy test procedures

 

Our personal use products enable individuals to monitor their health and wellness with the help of easy-to-perform, often noninvasive methods.

Products

ABI’s rapid, single-use products are performed in vitro (outside the body) and are designed to enhance patient well-being and reduce the total outcome costs of healthcare.

 

The Company’s current product offerings and pipeline products are…

 

 

  • easy to perform: helps reduce operator error and in the healthcare setting, potentially eliminates the need to outsource laboratory services
  • designed to deliver accurate results in minutes: provides real-time data that can be factored into time-sensitive treatment or wellness decisions
  • small in scale: accommodates workspace limitations in many laboratories and maximizes portability and convenience for over-the-counter products

 

 

Please select from USA or International products to access information related to tests that are available in your Region.

Board of Directors

 

John J. Gormally
Chief Executive Officer

John Gormally is an experienced medical technology specialist with a career spanning more than 30 years with the global medical technology company Becton Dickinson. He has considerable experience of managing large distribution networks as well as direct sales to hospitals and reference laboratories. Prior to joining Akers Bio in 2015, John served as Vice President, US Region Business Leader of Preanalytical Systems at Becton Dickinson where he led a multi-functional team of 92 associates in a business unit which contributed annual revenues of over $650 million. Prior to that role, John was Vice President, Worldwide Sales of Preanalytical Systems, leading a global sales function with 256 associates and annual revenues of $1.1 billion. John first joined Becton Dickinson in 1979 and climbed the sales and management ranks over twenty years within the Medical Surgical, Microbiology/Diagnostics and then Healthcare Systems divisions. John left Becton Dickinson in 1999 for several years to join Bristol-Myers Squibb Company, a global biopharmaceutical business focused on pharmaceutical and nutritional products. There he was accountable for a sales force/operations team of 226, with $450 million in annual revenue. He later joined BEI Medical Systems, a medical device start up, as Vice President, Global Sales and Marketing. John developed a successful commercial strategy and established a profitable business which was sold two years later, in 2003, to Boston Scientific for $95 million. Following the sale, John was recruited back to Becton Dickinson. John holds a B.S. Biology from DeSales University, PA.

George J. Awad
Director, Corporate and Legal Affairs

George Awad has 20 years of broadly based strategic corporate and legal affairs advisory experience. As a registered patent attorney, he has substantial experience in IP portfolio creation, management, and deployment experience in the USA, Europe and Asia. George has undertaken substantial IP portfolio strategy development and monetization, corporate transactions (M&A) and in/out licensing. He has collaborated with various technology companies ranging from Fortune 50 companies to start-ups (public and private) in a range of corporate and legal affairs matters through every stage of the corporate life cycle. George received a B.S.E. in Electrical Engineering from the Moore School of Electrical Engineering at the University of Pennsylvania where he was a member of the Hexagon Honor Society and a J.D. from Pepperdine University School of Law. George has also completed executive coursework in Accounting and Finance at the Wharton School of Business. He is a licensed attorney in PA and CA, and is a registered patent attorney with the United States Patent & Trademark Office.

Doug Carrara
Vice President, Global Marketing and Commercial Operations

Doug Carrara has over 25 years’ experience in the clinical diagnostics arena, particularly within sales, marketing and global operations. Doug joined Akers Bio in 2016 from Quest Diagnostics where he was the Senior Director of Strategic Accounts that led a team of directors responsible for developing and implementing strategic relationships within the acute care market. Prior to Quest Diagnostics, Doug worked for Becton Dickinson for 22 years in various leadership positions. In his last role there, as Director of Customer Solutions, Doug led a team that produced growth in revenues from a zero base to over $23 million in annual sales within a 3 year timeframe.

Tony Saporito
Vice President, US Sales and Distribution

Tony Saporito has a track record of building and leading high-performance businesses in the medical device and clinical diagnostics arenas for two decades. Prior to joining Akers Bio in 2016, Tony held the role of Strategic Account Executive with The Midmark Corporation, where he was responsible for driving new business through group purchasing organizations, integrated health systems and distribution. Prior to this role, Tony spent 10 years at ConvaTec, a former division of Bristol-Myers Squibb. In his last role there, Tony was responsible for an organization of 63 employees, generating annual revenues in excess of $65 million and averaging annual sales growth of approximately 20%.

Nicolas Daurel
Vice President, EMEA Sales and Marketing

Nicolas Daurel has a track-record of successfully building and managing the sales of medical devices in Europe, the Middle East and Africa (EMEA), particularly within the coagulation sector, for more than 20 years. He is based in Paris, France and is responsible for opening up new distribution channels in EMEA for the Company's core products. Nicolas was formerly Head of International Sales and Marketing for Trinity Biotech Plc, a public company specializing in the development, manufacture and marketing of clinical diagnostic products. During his time with Trinity, he was responsible for all coagulation business (excluding U.S.). From 1999 until shortly after its US$7 billion acquisition by Siemens AG in 2007, he held various positions with Dade Behring, a U.S.-headquartered manufacturer of equipment for the medical diagnostics industry. During his time with Dade Behring, among other responsibilities, Nicolas managed the Infectious Disease segment of their business, implementing multiple new products, and ultimately becoming Dade Behring's regional sales manager for France. Nicolas began his career in 1994 with Stago, an international manufacturer of testing systems within the haemostasis sector.

Gary M. Rauch
Vice President, Finance

Gary Rauch has over 35 years of experience in accounting, financial and information systems consulting, discrete manufacturing, distribution and administration. He founded DataSys Solutions, LLC in 2004 specializing in financial and information systems consulting and technical support services. From 2002-2010, he was the controller for Cold Star, Inc., a manufacturer of dairy dispensing equipment and a dairy products distributor. Gary served as Vice President of Information Systems for FYI, Inc. from 1992-2001, with responsibility for software design and development and other technical services to more than 600 hospitals utilizing FYI’s medical copy services. He was a consulting manager with Deloitte Touche from 1986-1992, providing financial system selection, development and implementation services for their small to middle market clients.

Richard E. McKee
Vice President, Engineering

Richard McKee has over 40 years in product design, development and consulting for automated manufacturing equipment in the medical diagnostics, pharmaceuticals, food, glass, and automotive industries. He is an Adjunct Professor of Engineering.

Contact Us
Akers Biosciences, Inc.
201 Grove Road
West Deptford, NJ 08086
USA
Tel: +1 (856) 848-8698
Email: [email protected]

Nominated Adviser & Broker

finnCap 

60 New Broad Street

London EC2M 1JJ 

UNITED KINGDOM

+44 (020 7220 0500

www.finncap.com

 

UK Transfer Agent

Capita Asset Services

The Registry

34 Beckenham Road

Beckenham, Kent BR3 4TU

UNITED KINGDOM

+44 (0) 871 664 0300

http://www.capitaassetservices.com

 

UK Investor Relations

Vigo Communications

One Berkeley Street

London W1J 8DJ

UNITED KINGDOM

+44(0) 20 7016 9570

http://www.vigocomms.com

 

US Investor Relations

RedChip Companies, Inc.

500 Winderley Place, Ste. 100

Maitland, FL 32751

USA

+1.407.644.4256

http://www.redchip.com

 

Attorneys

Lucosky Brookman LLP

101 Wood Avenue South

Woodbridge, New Jersey 08830

USA

+1.732.395.4400

http://www.lucbro.com/

 

Auditors

MorisonCogen LLP

150 Monument Road

Suite 500

Bala Cynwyd, Pennsylvania 19004

USA

+1.267.440.3000

http://www.morisoncogen.com

 

US Transfer Agent

VStock Transfer, LLC

77 Spruce Street

Suite 201

Cedarhurst, New York  11516

USA

+1.212.828.8436

www.VStockTransfer.com

Akers Biosciences, Inc. Timeline

Market Reports Including AKR

VIEW ALL
Video RSS

Videos

VIEW ALL VIDEOS
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC